NCT04912076 - S.C. Immunotherapy With BM41 in Patients With Allergic Rhino-conjunctivitis Caused by Birch Pollen | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 17, 2018

Primary Completion Date

March 22, 2019

Study Completion Date

March 22, 2019

Conditions

Birch Pollen AllergyAllergic Rhinoconjunctivitis

Interventions

DRUG

BM41

Subcutaneous injection of increasing doses of BM41

OTHER

Placebo

Subcutaneous injections of placebo containing aluminium hydroxide.

DRUG

ALK Alutard SQ Betula verrucosa

Subcutaneous injections with increasing doses of Alutard according to cluster up-dosing scheme.

Trial Locations (1)

Odense Research Center for Anaphylaxis, Odense University Hospital, Odense